KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Intangibles (2017 - 2026)

Amneal Pharmaceuticals has reported Intangibles over the past 9 years, most recently at $563.5 million for Q4 2025.

  • For Q4 2025, Intangibles fell 23.06% year-over-year to $563.5 million; the TTM value through Dec 2025 reached $563.5 million, down 23.06%, while the annual FY2025 figure was $563.5 million, 23.06% down from the prior year.
  • Intangibles for Q4 2025 was $563.5 million at Amneal Pharmaceuticals, down from $587.9 million in the prior quarter.
  • Over five years, Intangibles peaked at $1.3 billion in Q2 2021 and troughed at $563.5 million in Q4 2025.
  • A 5-year average of $962.5 million and a median of $999.0 million in 2023 define the central range for Intangibles.
  • Biggest five-year swings in Intangibles: fell 4.21% in 2022 and later fell 24.64% in 2025.
  • Year by year, Intangibles stood at $1.2 billion in 2021, then fell by 6.07% to $1.1 billion in 2022, then dropped by 18.76% to $890.4 million in 2023, then dropped by 17.75% to $732.4 million in 2024, then fell by 23.06% to $563.5 million in 2025.
  • Business Quant data shows Intangibles for AMRX at $563.5 million in Q4 2025, $587.9 million in Q3 2025, and $649.5 million in Q2 2025.